|
KMID : 1134120220250010049
|
|
Journal of Breast Cancer
2022 Volume.25 No. 1 p.49 ~ p.56
|
|
|
CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience
|
|
Jang Yoon-Jung
Jeong Jae-Ho
Kim Jeong-Eun
Ahn Jin-Hee
Jung Kyung-Hae
Kim Sung-Bae
|
|
|
Abstract
|
|
|
|
This single-institute, retrospective cohort study enrolled patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab deruxtecan between August 2017 and January 2021 from four previous studies. Of 31 patients, 4 (12.9%) had interstitial lung disease (ILD). The dominant pattern observed on computed tomography was organizing pneumonia (100%), comprising subpleural consolidations in the lung periphery. However, no dominant distribution was observed in radiological lesions of the lungs. Of all the tested patients, lower lobe predominance was noted in 2 (50.0%) patients, upper lobe predominance in 1 (25.0%) patient, and diffused lobe distribution in 1 (25.0%) patient. All events were confined to the Common Terminology Criteria for Adverse Events grade 1 or 2 (100%). None of the patients died. Despite the small number of cases investigated, the incidence of trastuzumab deruxtecan-induced ILD in the Korean population was comparable to that previously reported.
|
|
|
KEYWORD
|
|
|
Breast Neoplasms, Genes, erbB-2, Lung Diseases, Interstitial, Tomography, X-ray Computed, Trastuzumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|